



Published in final edited form as:

J Rheumatol Suppl. 2012 July ; 89: 24–28. doi:10.3899/jrheum.120237.

Metabolic Syndrome in Patients with Psoriatic Disease

**Joel M. Gelfand, MD, MSCE [Assistant Professor of Dermatology and Epidemiology] and
Howa Yeung, BS [Pre-doctoral Research Fellow]**

Department of Dermatology and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

Joel M. Gelfand: joel.gelfand@uphs.upenn.edu; Howa Yeung: howa.yeung@uphs.upenn.edu

Abstract

Psoriasis is a common Th-1 and Th-17-mediated chronic inflammatory disease that has been associated with metabolic syndrome, a constellation of cardiovascular risk factors including obesity, hypertension, dyslipidemia, and insulin resistance, has been implicated. Overlapping inflammatory pathways and genetic susceptibility may be potential biologic links underlying this association. Multiple epidemiologic studies have consistently demonstrated higher prevalence of metabolic syndrome in patients with psoriasis. Dose-response relationships between more severe psoriasis and higher prevalence of metabolic syndrome components were recently established. This association has important clinical implications for the comprehensive management of psoriasis: Patients with psoriasis should be routinely screened for metabolic syndrome and treated accordingly to manage cardio-metabolic risk, while clinicians should monitor potential effects on treatment efficacy and safety in patients with co-morbid psoriasis and metabolic syndrome. Further research will be necessary to establish the directionality of this association and to explore the impact of treatment on these co-morbid diseases.

Key Indexing Terms

Psoriasis; Metabolic Syndrome; Dyslipidemia; Hyperglycemia; Obesity

Psoriasis is a common, chronic inflammatory disease that is associated with significant impairment in health-related quality of life even in mild cases, and excess cardiovascular and all-cause mortality in patients with more severe disease.(1–5) Based on an increasing understanding of its immune pathophysiology, psoriasis is now thought to be a systemic disease with potential health implications beyond the skin.(6–8) This topic is of critical importance because emerging data suggest that patients with more severe presentations of psoriatic disease have a 50% increased risk of mortality that results in approximately 5 years of life lost.(9) Of special interest, diseases which share a similar immune-pathophysiology with psoriasis have been investigated as co-morbid outcomes. For example, Th-1 and Th-17 immune pathways which drive psoriasis are also prominent disease mediators for atherosclerosis and thrombosis.(10) A variety of studies have suggested that patients with psoriasis have an increased risk of myocardial infarction, stroke, vascular inflammation and atherosclerotic conditions independent of traditional risk factors for cardiovascular disease. (6, 11–24) Similarly, metabolic syndrome, which is a clustering of cardiovascular risk

Address requests for reprints and correspondence to Dr. Joel M. Gelfand, 1471 Penn Tower, One Convention Avenue, Philadelphia, PA 19104, USA. Telephone: (215) 614-0635, Fax: (215) 746-6370, joel.gelfand@uphs.upenn.edu.

Financial Disclosure: Dr. Gelfand served as consultant with Abbott, Amgen, Celgene, Centocor, Novartis, and Pfizer, receiving honoraria; had grants or has pending grants from Abbott, Amgen, Genentech, Novartis, and Pfizer; and received payment for CME work related to psoriasis. Mr. Yeung has no financial disclosures to report.

factors, specifically obesity, hypertension, dyslipidemia, and insulin resistance, is associated with chronic inflammation.(25, 26) In this review, which is based on a lecture (given by JMG) at the Second Update on Psoriatic Disease in Naples, Italy, we will focus on the expanding literature linking metabolic syndrome to psoriasis and highlight some of the clinical implications of this finding.

The underlying pathophysiology linking psoriasis and metabolic syndrome may involve overlapping inflammatory pathways and genetic predisposition.(27, 28) Chronic Th-1 and Th-17-mediated inflammation with dysregulation of cytokines, e.g. tumor necrosis factor- α and interleukin-6, not only promotes epidermal hyperplasia in psoriasis, but may also antagonize insulin signaling, alter adipokine expression, and mediate insulin resistance and obesity.(27, 28) Conversely, hyperinsulinemia in metabolic syndrome may promote psoriasis susceptibility or severity by facilitating chronic inflammation and angiogenesis. (27, 28) In addition, the existence of pleiotropic genetic loci, e.g., PSORS2-4, CDKAL1, and ApoE4, has also been implicated in the shared genetic susceptibility to both psoriasis and metabolic syndrome.(28) These shared mechanisms underscore the biological plausibility for the association between psoriasis and metabolic syndrome.

In 2006, the first studies directly linking components of metabolic syndrome to psoriasis using multivariate analyses started to emerge. For example, in a population-based, cross-sectional study in the United Kingdom, it was shown that psoriasis was associated with diabetes independent of diabetes risk factors (such as obesity) and that the association was stronger in patients with more severe disease.(29) The increased prevalence of metabolic syndrome among patients with psoriasis has been replicated in multiple countries including Italy, Israel, India, Japan, China, Tunisia, and the United States.(30–37) Additionally, an increased prevalence of metabolic syndrome has been specifically observed among patients with psoriatic arthritis with studies suggesting that the association is specific for psoriatic arthritis compared to other inflammatory arthropathies such as rheumatoid arthritis and ankylosing spondylitis.(38, 39) Finally, emerging data suggest that the association of psoriasis with metabolic syndrome occurs early in the course of the disease as psoriasis is associated with obesity and elevated lipids even in childhood.(40) While these prevalence studies clearly establish an association between psoriasis and metabolic syndrome, they cannot establish the directionality of the association. Several studies suggest that obesity, a primary component of metabolic syndrome, is a risk factor for future development of psoriasis with an estimated 30% of new psoriasis cases being attributable to obesity.(41, 42) Alternatively, several studies indicate that psoriasis patients are prone to the future development of key components of metabolic syndrome such as diabetes, independent of traditional risk factors.(43, 44)

The relationship between psoriasis, metabolic syndrome, and its individual components was further elucidated in a recent large-scaled, population-based prevalence study in the UK.(45) Using objective measures of body surface area involvement of psoriasis and direct measurements of metabolic syndrome components, the study showed that increasing psoriasis severity was associated with higher odds of metabolic syndrome (Figure 1). The relationship remained robust to different definitions of metabolic syndrome. Of note, several components of the metabolic syndrome – namely, obesity, hypertriglyceridemia and hyperglycemia – demonstrated dose-response associations with psoriasis severity that are independent of other components (Figure 2). These results suggest that psoriasis severity is a driving factor behind metabolic disorders so frequently seen in this patient population, or alternatively, that metabolic disorders lead to worsening severity of psoriasis.

Importantly, this broad and expanding literature linking psoriasis with metabolic syndrome has clinical applications relevant to daily practice especially as it relates to the efficacy and

safety of commonly used systemic medications. For example, more aggressive liver monitoring guidelines (including the requirement of more frequent liver biopsies) are recommended for psoriasis patients with components of the metabolic syndrome (obesity, diabetes) who are taking methotrexate.(46) Of note, psoriasis patients have been shown to have an increased frequency and severity of non-alcoholic fatty liver disease and thus caution may be indicated when using medications with liver toxicity such as methotrexate and acitretin.(47) Moreover, increasing body mass index is associated with a reduction in psoriasis treatment efficacy, especially among non-weight based biologic therapies.(48) Finally, emerging observational data suggest that successful systemic treatment of psoriasis may be associated with improvement in metabolic risk biomarkers.(49) Randomized controlled studies evaluating hard clinical endpoints will be necessary to determine if the improvement in metabolic function detected in observational settings translates into clinically meaningful improvements in health outcomes.

Given the association of psoriasis with metabolic syndrome and the impact it has on the patient's health and on the efficacy and safety of treatment options, it is important that patients undergo appropriate screening as part of routine medical care.(50, 51) Routine United States-based recommendations for all patients (not just those with psoriasis) include a blood pressure check at each office visit in patients 21 or older, a fasting glucose every 3 years in patients 45 or older (or younger in patients with risk factors for diabetes), and cholesterol screening every 5 years starting at age 20.(52–54) Additionally, as patients with psoriasis have an increased risk of cardiovascular disease, clinicians may consider setting more stringent goals for blood pressure and cholesterol levels in these patients as has been advocated for patients with other Th1 diseases such as rheumatoid arthritis.(55, 56)

In summary, a broad and evolving literature supports that psoriasis is associated with metabolic syndrome. This association has clinical implications for the care of patients with psoriasis in terms of screening for metabolic syndrome in these patients, taking steps at lowering cardiovascular risk in patients with psoriasis, and recognizing the impact metabolic syndrome may have on the safety and efficacy of psoriasis therapeutics. Rigorous clinical trials are necessary to determine if successful treatment of psoriasis will lower the risk of developing metabolic syndrome and its complications.

Acknowledgments

Source of Support: This study was supported by grants from NIH National Heart, Lung, and Blood Institute R01-HL089744 (JMG) and National Institutes of Arthritis and Musculoskeletal and Skin Disease T32-AR07465 (HY).

References

1. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003–2004. *J Am Acad Dermatol.* 2009 Feb; 60(2):218–24. [PubMed: 19022533]
2. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. *JAMA.* 2006 Oct 11; 296(14):1735–41. [PubMed: 17032986]
3. Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinants of quality of life in patients with psoriasis: a study from the US population. *J Am Acad Dermatol.* 2004 Nov; 51(5):704–8. [PubMed: 15523347]
4. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. *Eur Heart J.* 2010 Apr; 31(8):1000–6. [PubMed: 20037179]
5. Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, et al. The risk of mortality in patients with psoriasis: results from a population-based study. *Arch Dermatol.* 2007 Dec; 143(12):1493–9. [PubMed: 18086997]

6. Mehta NN, Yu Y, Saboury B, Foroughi N, Krishnamoorthy P, Raper A, et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. *Arch Dermatol.* 2011 Sep; 147(9):1031–9. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. [PubMed: 21576552]
7. Boehncke WH, Boehncke S, Schon MP. Managing comorbid disease in patients with psoriasis. *BMJ.* 2010; 340:b5666. [Review]. [PubMed: 20080817]
8. Menter A, Griffiths CE, Tebbey PW, Horn EJ, Sterry W. Exploring the association between cardiovascular and other disease-related risk factors in the psoriasis population: the need for increased understanding across the medical community. *J Eur Acad Dermatol Venereol.* 2010 Dec; 24(12):1371–7. [Research Support, Non-U.S. Gov't Review]. [PubMed: 20384692]
9. Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. *Br J Dermatol.* 2010 Sep; 163(3):586–92. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. [PubMed: 20633008]
10. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med.* 2005 Apr 21; 352(16):1685–95. [PubMed: 15843671]
11. Gelfand JM, Dommasch ED, Shin DB, Azfar RS, Kurd SK, Wang X, et al. The risk of stroke in patients with psoriasis. *J Invest Dermatol.* 2009 Oct; 129(10):2411–8. [PubMed: 19458634]
12. Ludwig RJ, Herzog C, Rostock A, Ochsendorf FR, Zollner TM, Thaci D, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. *Br J Dermatol.* 2007 Feb; 156(2):271–6. [Research Support, Non-U.S. Gov't]. [PubMed: 17223866]
13. Balci DD, Balci A, Karazincir S, Ucar E, Iyigun U, Yalcin F, et al. Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis. *J Eur Acad Dermatol Venereol.* 2009 Jan; 23(1):1–6. [PubMed: 18702627]
14. Gisondi P, Fantin F, Del Giglio M, Valbusa F, Marino F, Zamboni M, et al. Chronic plaque psoriasis is associated with increased arterial stiffness. *Dermatology.* 2009; 218(2):110–3. [PubMed: 19060461]
15. Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT. Cardiovascular morbidity in psoriatic arthritis. *Ann Rheum Dis.* 2009 Jul; 68(7):1131–5. [Research Support, Non-U.S. Gov't]. [PubMed: 18697777]
16. Brauchli YB, Jick SS, Miret M, Meier CR. Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. *Br J Dermatol.* 2009 May; 160(5):1048–56. [PubMed: 19210501]
17. Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. *Arch Dermatol.* 2009 Jun; 145(6):700–3. [Comparative Study]. [PubMed: 19528427]
18. Bicer A, Acikel S, Kilic H, Ulukaradag Z, Karasu BB, Cemil BC, et al. Impaired aortic elasticity in patients with psoriasis. *Acta cardiologica.* 2009 Oct; 64(5):597–602. [Comparative Study]. [PubMed: 20058504]
19. El-Mongy S, Fathy H, Abdelaziz A, Omran E, George S, Neseem N, et al. Subclinical atherosclerosis in patients with chronic psoriasis: a potential association. *J Eur Acad Dermatol Venereol.* 2010 Jun; 24(6):661–6. [PubMed: 19888942]
20. Ulusoy RE, Karabudak O, Yokusoglu M, Kilicaslan F, Kirilmaz A, Cebeci BS. Noninvasive assessment of impaired endothelial function in psoriasis. *Rheumatology international.* 2010 Feb; 30(4):479–83. [PubMed: 19529939]
21. Xiao J, Chen LH, Tu YT, Deng XH, Tao J. Prevalence of myocardial infarction in patients with psoriasis in central China. *J Eur Acad Dermatol Venereol.* 2009 Nov; 23(11):1311–5. [Research Support, Non-U.S. Gov't]. [PubMed: 19522710]
22. Ahlehoff O, Gislason GH, Charlott M, Jorgensen CH, Lindhardsen J, Olesen JB, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. *J Intern Med.* 2010 Oct 29.

23. Lin HW, Wang KH, Lin HC. Increased risk of acute myocardial infarction in patients with psoriasis: a 5-year population-based study in Taiwan. *J Am Acad Dermatol*. 2011 Mar; 64(3):495–501. [PubMed: 21216492]
24. Ahlehoff O, Gislason GH, Lindhardsen J, Olesen JB, Charlott M, Skov L, et al. Prognosis following first-time myocardial infarction in patients with psoriasis: a Danish nationwide cohort study. *J Intern Med*. 2011 Mar 1.
25. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. *Lancet* [Review]. 2005 Apr 16–22; 365(9468):1415–28.
26. Monteiro R, Azevedo I. Chronic inflammation in obesity and the metabolic syndrome. *Mediators Inflamm* [Review]. 2010; 2010
27. Davidovici BB, Sattar N, Prinz JC, Puig L, Emery P, Barker JN, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. *J Invest Dermatol*. 2010 Jul; 130(7):1785–96. [Review]. [PubMed: 20445552]
28. Azfar RS, Gelfand JM. Psoriasis and metabolic disease: epidemiology and pathophysiology. *Current opinion in rheumatology*. 2008 Jul; 20(4):416–22. [Research Support, N.I.H., Extramural Review]. [PubMed: 18525354]
29. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. *J Am Acad Dermatol*. 2006 Nov; 55(5):829–35. [Research Support, N.I.H., Extramural]. [PubMed: 17052489]
30. Cohen AD, Gilutz H, Henkin Y, Zahger D, Shapiro J, Bonneh DY, et al. Psoriasis and the metabolic syndrome. *Acta Derm Venereol*. 2007; 87(6):506–9. [PubMed: 17989888]
31. Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J. Association between psoriasis and the metabolic syndrome. A cross-sectional study. *Dermatology*. 2008; 216(2):152–5. [PubMed: 18216477]
32. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. *Br J Dermatol*. 2007 Jul; 157(1):68–73. [PubMed: 17553036]
33. Li F, Jin HZ, Wang BX. Prevalence of metabolic syndrome in psoriasis inpatients in Peking Union Medical College Hospital. *Zhongguo yi xue ke xue yuan xue bao Acta Academiae Medicinae Sinicae*. 2010 Oct; 32(5):583–5. [PubMed: 21054959]
34. Love TJ, Qureshi AA, Karlson EW, Gelfand JM, Choi HK. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003–2006. *Arch Dermatol*. 2011 Apr; 147(4):419–24. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. [PubMed: 21173301]
35. Mebazaa A, El Asmi M, Zidi W, Zayani Y, Cheikh Rouhou R, El Ounifi S, et al. Metabolic syndrome in Tunisian psoriatic patients: prevalence and determinants. *J Eur Acad Dermatol Venereol*. 2011 Jun; 25(6):705–9. [PubMed: 21029207]
36. Nisa N, Qazi MA. Prevalence of metabolic syndrome in patients with psoriasis. *Indian journal of dermatology, venereology and leprology [Comparative Study]*. 2010 Nov-Dec; 76(6):662–5.
37. Takahashi H, Takahashi I, Honma M, Ishida-Yamamoto A, Iizuka H. Prevalence of metabolic syndrome in Japanese psoriasis patients. *J Dermatol Sci*. 2010 Feb; 57(2):143–4. [Comparative Study Letter]. [PubMed: 20005080]
38. Mok CC, Ko GT, Ho LY, Yu KL, Chan PT, To CH. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. *Arthritis care & research*. 2011 Feb; 63(2):195–202. [Clinical Trial Comparative Study]. [PubMed: 20890981]
39. Raychaudhuri SK, Chatterjee S, Nguyen C, Kaur M, Jialal I, Raychaudhuri SP. Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. *Metabolic syndrome and related disorders*. 2010 Aug; 8(4):331–4. [Research Support, N.I.H., Extramural]. [PubMed: 20367239]
40. Koebnick C, Black MH, Smith N, Der-Sarkissian JK, Porter AH, Jacobsen SJ, et al. The association of psoriasis and elevated blood lipids in overweight and obese children. *The Journal of pediatrics*. 2011 Oct; 159(4):577–83. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. [PubMed: 21524758]

41. Naldi L, Chatenoud L, Linder D, Belloni Fortina A, Peserico A, Virgili AR, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. *J Invest Dermatol*. 2005 Jul; 125(1):61–7. [Research Support, Non-U.S. Gov't]. [PubMed: 15982303]
42. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. *Arch Intern Med*. 2007 Aug 13–27; 167(15):1670–5. [PubMed: 17698691]
43. Brauchli YB, Jick SS, Meier CR. Psoriasis and the risk of incident diabetes mellitus: a population-based study. *Br J Dermatol*. 2008 Dec; 159(6):1331–7. [PubMed: 18782318]
44. Qureshi AA, Choi HK, Setty AR, Curhan GC. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. *Arch Dermatol*. 2009 Apr; 145(4):379–82. [PubMed: 19380659]
45. Langan SM, Seminara NM, Shin DB, Troxel AB, Kimmel SE, Mehta NN, et al. Prevalence of Metabolic Syndrome in Patients with Psoriasis: A Population-Based Study in the United Kingdom. *J Invest Dermatol*. 2011 Nov 24.
46. Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. *J Am Acad Dermatol*. 2009 May; 60(5):824–37. [Consensus Development Conference]. [PubMed: 19389524]
47. Miele L, Vallone S, Cefalo C, La Torre G, Di Stasi C, Vecchio FM, et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. *Journal of hepatology*. 2009 Oct; 51(4):778–86. [Research Support, Non-U.S. Gov't]. [PubMed: 19664838]
48. Clark L, Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. *J Am Acad Dermatol*. 2008 Mar; 58(3):443–6. [Review]. [PubMed: 18083274]
49. Boehncke S, Salgo R, Garbaraviciene J, Beschmann H, Hardt K, Diehl S, et al. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study. *J Eur Acad Dermatol Venereol*. 2011 Jan 17.
50. Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. *J Am Acad Dermatol*. 2008 Jun; 58(6):1031–42. [PubMed: 18313171]
51. Friedewald VE, Cather JC, Gelfand JM, Gordon KB, Gibbons GH, Grundy SM, et al. AJC editor's consensus: psoriasis and coronary artery disease. *Am J Cardiol*. 2008 Dec 15; 102(12):1631–43. [PubMed: 19064017]
52. U.S. Preventive Services Task Force. Guide to clinical preventive services: report of the US Preventive Services Task Force. 2. Washington, DC: U.S. Dept. of Health and Human Services; 1996.
53. American Diabetes Association. Screening for type 2 diabetes. *Diabetes care*. 2004 Jan; 27(Suppl 1):S11–4. [Guideline]. [PubMed: 14693922]
54. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA*. 2001 May 16; 285(19):2486–97. [Guideline Practice Guideline]. [PubMed: 11368702]
55. Mehta NN, Yu Y, Pinnelas R, Krishnamoorthy P, Shin DB, Troxel AB, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. *Am J Med*. 2011 Aug; 124(8):775, e1–6. [Comparative Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. [PubMed: 21787906]
56. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. *Ann Rheum Dis*. 2010 Feb; 69(2):325–31. [PubMed: 19773290]




Figure 1. Increasing psoriasis severity is associated with increasing odds of metabolic syndrome. OR, odds ratio; BSA, body surface area affected. Model adjusted for age and sex.




Figure 2.

Increasing psoriasis severity is associated with increasing odds of metabolic syndrome components independent of other components.

OR, odds ratio; BSA, body surface area affected. Model adjusted for age, sex, and other components of metabolic syndrome.